MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
FAIL · Does not pass the screen
48.50 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 6 days ago
Screened 2026-10-23 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price48.50 USD at the 23 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans to puts (put/call 1.07)
Last reviewed23 Oct 2026 (6 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 48.50 against the desk's fair-value range, base estimate 88.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.07, read 2026-10-24
Ethical does not pass the values gate
Price48.50 USD
Fair value88.00
Ethical score70.0/100
Our investment reviews on this name
2026-09-05Read Markdown66.39-26.9% to today ✓Markup gives way to Markdown after an 87% rise in 9 weeks
2026-07-02Read Markup35.51+36.6% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
MBX Biosciences, Inc. holds its Markdown at $48.50. Consolidating, no directional conviction, held for 48 days.
As held on the ledger · 2026-10-23
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 48 days
Price at the screen
$48.50
Valuation
N/A trailing · -12.69 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.10
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.15%
Below 33%
Interest-bearing debt is just 0.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
77.48%
Below 33%
Interest-bearing cash and securities are 77.5% of assets, above the one-third limit.
Fail
Receivables
20.10%
Below 49%
Money owed to the company is 20.1% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
MBX Biosciences,'s business is fine, but its cash and interest-bearing securities are about 77% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when MBX's ethical verdict changes
Today MBX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 81.4% margin of safety to the base estimate.
Third-party analyst targets: 10 covering, consensus Strong Buy. The average target sits +81% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clinical stage biotech with zero profits
A clinical stage biotech is a bit like backing an untested athlete to win the Olympics, you pay upfront for potential that may never arrive. MBX Biosciences focuses on peptide therapies for endocrine disorders, with its lead candidate still in trials and no approved products. The numbers show a forward P/E of negative 16 times, zero profit margin and return on equity at negative 26 percent, which is why the opportunity rating stays at none.
Analysts give a strong buy call with a 70 dollar median target against the current 62.92 price, yet the ethical screen returns insufficient data because basic financial ratios are missing. That gap alone blocks any positive view here.
High clinical failure rates remain the core risk for any early stage drug maker, and the lack of moat or ethical clarity adds further uncertainty around long term viability. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MBX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-25Markdown$50.46+3.0%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 18% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 165%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (11 analysts) rates it none, with a mean price target of $69.
2026-10-18Markdown$49.00-19.6%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 19.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 165%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (11 analysts) rates it none, with a mean price target of $69.
2026-10-02Markdown$60.94-8.2%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 165%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (11 analysts) rates it none, with a mean price target of $69.
2026-09-05Markdown · changed$66.39+5.5%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 5.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 165%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (11 analysts) rates it none, with a mean price target of $69.
2026-08-05Markup$62.92+77.2%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 77.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 165%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (11 analysts) rates it none, with a mean price target of $69.
2026-07-18Markup$35.51+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 165%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (11 analysts) rates it none, with a mean price target of $69.
2026-07-03Markup$35.51+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$35.51Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
